MW-189 is under clinical development by ImmunoChem Therapeutics and currently in Phase I for Subarachnoid Hemorrhage. According to GlobalData, Phase I drugs for Subarachnoid Hemorrhage have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MW-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MW-189 overview

MW-189 is under development for the treatment of for the treatment of Alzheimer's disease (AD), aneurysmal subarachnoid hemorrhage, rheumatoid arthritis (RA), intracerebral hemorrhage (ICH), traumatic brain injury (TBI) and neuropathic pain. The drug candidate is administered by intravenous injection or orally. The drug candidate acts by targeting the overproduction of inflammatory cytokines, such as interleukin-1 (IL-1beta), tumour necrosis factor-alpha (TNF-alpha).

For a complete picture of MW-189’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.